

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. **(Canceled)**
2. **(Currently Amended)** The antibody of any one of claims 99-102 ~~claim 51 or 52~~, selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, a secretory IgA, an IgD, and an IgE antibody.
3. **(Currently Amended)** The antibody of any one of claims 99-102 ~~claim 2~~, wherein the antibody is an IgG1 antibody.
4. **(Currently Amended)** The antibody of any one of claims 99-102 ~~claim 2~~, wherein the antibody is an IgG4 antibody.
5. **(Currently Amended)** The antibody of any one of claims 99-102 ~~claim 51 or 52~~, wherein the antibody dissociates from human CD25 with a dissociation equilibrium constant (K_D) of ~~about~~ 10^{-8} M or less, ~~preferably of about 10^{-9} M or less, and more preferably of about 10^{-10} M or less, or 10^{-11} M or even less,~~ when determined by surface plasmon resonance (SPR) technology in a BIAcore 3000 instrument using human recombinant CD25 as the ligand and the antibody as the analyte.
6. **(Currently Amended)** The antibody of any one of claims 99-102 ~~claim 51 or 52~~, wherein the antibody has one or more of the following characteristics:
 - (a) specificity for human CD25;
 - (b) inhibits binding of IL-2 to CD25;
 - (c) eliminates T cells expressing CD25;
 - (d) tolerizes T cells;
 - (e) inhibits proliferation of T cells expressing CD25;
 - (f) inhibits anti-CD3 antibody-induced T cell proliferation of peripheral blood mononuclear cells (PBMCs);

- (g) inhibits mixed lymphocyte reaction (MLR);
- (h) internalization of CD25 expressed on T cells.

7. **(Currently Amended)** ~~The~~ An isolated monoclonal antibody ~~of claim 51 which binds to human CD25,~~ encoded by human heavy chain and human kappa light chain nucleic acids comprising nucleotide sequences in their variable regions as set forth in SEQ ID NO:5 and SEQ ID NO:7, respectively, ~~or conservative sequence modifications thereof.~~

8. **(Currently Amended)** ~~The~~ An isolated monoclonal antibody ~~of claim 51 which binds to human CD25,~~ encoded by human heavy chain and human kappa light chain nucleic acids comprising nucleotide sequences in their variable regions as set forth in SEQ ID NO:13 and SEQ ID NO:15, respectively, ~~or conservative sequence modifications thereof.~~

9. **(Currently Amended)** ~~The~~ An isolated monoclonal antibody ~~of claim 52 which binds to human CD25,~~ encoded by human heavy chain and human kappa light chain nucleic acids comprising nucleotide sequences in their variable regions as set forth in SEQ ID NO:1 and SEQ ID NO:3, respectively, ~~or conservative sequence modifications thereof.~~

10. **(Currently Amended)** ~~The~~ An isolated monoclonal antibody ~~of claim 51 which binds to human CD25,~~ encoded by human heavy chain and human kappa light chain nucleic acids comprising nucleotide sequences in their variable regions as set forth in SEQ ID NO:9 and SEQ ID NO:11, respectively, ~~or conservative sequence modifications thereof.~~

11. **(Currently Amended)** ~~The~~ An isolated monoclonal antibody ~~of claim 51 which binds to human CD25,~~ having a human heavy chain and human kappa light chain variable regions comprising the amino acid sequences as set forth in SEQ ID NO:6 and SEQ ID NO:8, respectively, ~~or conservative sequence modifications thereof.~~

12. **(Canceled)**

13. **(Currently Amended)** ~~The~~ An isolated monoclonal antibody ~~of claim 51 which~~ binds to human CD25, having a human heavy chain and human kappa light chain variable regions comprising the amino acid sequences as set forth in SEQ ID NO:14 and SEQ ID NO:16, respectively, ~~or conservative sequence modifications thereof.~~

14. **(Canceled)**

15. **(Currently Amended)** ~~The~~ An isolated monoclonal antibody ~~of claim 52 which~~ binds to human CD25, having a human heavy chain and human kappa light chain variable regions comprising the amino acid sequences as set forth in SEQ ID NO:2 and SEQ ID NO:4, respectively, ~~or conservative sequence modifications thereof.~~

16. **(Canceled)**

17. **(Currently Amended)** ~~The~~ An isolated monoclonal antibody ~~of claim 52~~ having a human heavy chain and human kappa light chain variable regions comprising the amino acid sequences as set forth in SEQ ID NO:10 and SEQ ID NO:12, respectively, ~~or conservative sequence modifications thereof.~~

18. **(Canceled)**

19. **(Currently Amended)** ~~The~~ An isolated monoclonal antibody ~~of claim 51 or 52~~, comprising at least one human variable region selected from the group consisting of:

- (i) SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, and 16; ~~and~~
- ~~(ii) a sequence which is at least 90% homologous to any one of the amino acid sequences as set forth in (i).~~

20. **(Currently Amended)** An isolated human monoclonal antibody which binds to an epitope on human CD25 defined by the antibody of any one of claims 99-102 ~~claim 7~~.

21. **(Currently Amended)** An isolated human monoclonal antibody which has the binding characteristics of the antibody of any one of claims 99-102 ~~claim 7~~.

22-39. **(Canceled)**

40. **(Currently Amended)** The antibody of any one of claims 99-102 ~~claim 51 or 52~~, comprising a V_H CDR1 domain having the amino acid sequence

X₁-Tyr-X₂-Ile-X₃ **(SEQ ID NO: 73)**

wherein X₁, X₂ and X₃ are natural amino acids; and

wherein X₁ is different from Ser; or X₂ is different from Ala; or X₃ is different from Ser.

41. **(Previously Presented)** The antibody of claim 40, wherein X₁ is Arg, Lys or His; X₂ is Ala, Gly, Val, Leu, Ile, or Pro; and X₃ is Asn or Gln **(SEQ ID NO: 74)**.

42. **(Previously Presented)** The antibody of claim 41, wherein X₁ is Arg; X₂ is Ala, Ile, or Pro; and X₃ is Asn **(SEQ ID NO: 62)**.

43. **(Currently Amended)** The antibody of any one of claims 99-102 ~~claim 51 or 52~~, comprising a V_H CDR2 domain having the amino acid sequence

Arg-Ile-Ile-Pro-Ile-Leu-Gly-X₁-X₂-X₃-Tyr-Ala-Gln-X₄-Phe-Gln-X₅ **(SEQ ID NO: 63)**

wherein X₁, X₂, X₃, X₄, and X₅ are natural amino acids; and

wherein X₁ is different from Ile; or X₂ is different from Ala; or X₃ is different from Asn; or X₄ is different from Lys; or X₅ is different from Gly.

44. **(Previously Presented)** The antibody of claim 43, wherein X₁ is Ile, Val, Gly, Ala or Leu; X₂ is Ala, Ile, Val, Gly, Leu, Glu or Asp; X₃ is Asp, Glu, Asn or Gln; X₄ is Lys, Arg or His; and X₅ is Gly, Ile, Val, Ala, Leu, Asp or Glu (SEQ ID NO: 64).

45. **(Previously Presented)** The antibody of claim 44, wherein X₁ is Ile or Val; X₂ is Ala or Glu; X₃ is Asp or Asn; X₄ is Lys or Arg; and X₅ is Gly or Asp (SEQ ID NO: 65).

46. **(Currently Amended)** The antibody of any one of claims 99-102 ~~claim 51 or 52~~, comprising a V_L CDR1 domain having the amino acid sequence

Arg-Ala-Ser-Gln-Ser-X₁-Ser-Ser-X₂-Leu-Ala (SEQ ID NO: 66)

wherein X₁ and X₂ are natural amino acids; and

wherein X₁ is different from Val; or X₂ is different from Tyr.

47. **(Original)** The antibody of claim 46, wherein X₁ is Val, Ala, Leu, Ile or Gly; and X₂ is Phe, Trp or Tyr.

48. **(Previously Presented)** The antibody of claim 47, wherein X₁ is Val or Gly; and X₂ is Phe or Tyr (SEQ ID NO: 67).

49. **(Currently Amended)** The antibody of any one of claims 99-102 ~~claim 51 or 52~~, comprising a V_L CDR3 domain having the amino acid sequence

Gln-Gln-Tyr-X₁-Ser-Ser-Pro-X₂-X₃ (SEQ ID NO: 69)

wherein X₁ is Gly, Ala, Val, Leu, Ile, Ser or Thr; X₂ is Leu, Gly, Ala, Val or Ile; and X₃ is Thr or Ser.

50. **(Previously Presented)** The antibody of claim 49, wherein X₁ is Gly or Ser, X₂ is Leu or Ile; and X₃ is Thr (SEQ ID NO: 70).

51-52. (Canceled)

53. **(Currently Amended)** The antibody of any one of claims 99-102 ~~claim 51 or 52~~, which is an intact antibody selected from the group consisting of an intact IgG1 antibody, an intact IgG2 antibody, an intact IgG3 antibody, an intact IgG4 antibody, an intact IgM antibody, an intact IgA1 antibody, an intact IgA2 antibody, an intact secretory IgA antibody, an intact IgD antibody, and an intact IgE antibody, wherein the antibody is glycosylated in a eukaryotic cell.

54. **(Currently Amended)** The antibody of any one of claims 99-102 ~~claim 51 or 52~~, which is an intact antibody selected from the group consisting of an intact IgG1, κ antibody, an intact IgG1, λ antibody, an intact IgG4, κ antibody, and an intact IgG4, λ antibody, wherein the antibody is glycosylated in a eukaryotic cell.

55. **(Currently Amended)** The antibody of any one of claims 99-102 ~~claim 51 or 52~~ which is an antibody fragment or a single chain antibody.

56. **(Original)** An isolated human monoclonal antibody which binds to human CD25 and inhibits IL-2 binding to CD25 which is a binding-domain immunoglobulin fusion protein comprising (i) a heavy chain variable region or a light chain variable region as defined in claim 19, that is fused to an immunoglobulin hinge region polypeptide, (ii) an immunoglobulin heavy chain CH2 constant region fused to the hinge region, and (iii) an immunoglobulin heavy chain CH3 constant region fused to the CH2 constant region.

57-66. (Canceled)

67. **(Currently Amended)** The antibody of any one of claims 99-102 ~~claim 51 or 52~~, further comprising a chelator linker for attaching a radioisotope.

68-98. (Canceled)

99. **(Previously Presented)** An isolated human monoclonal antibody which binds to human CD25 and inhibits IL-2 binding to CD25, wherein the antibody comprises a human heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:35, 36, and 37, respectively, and a human light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:38, 39, and 40, respectively.

100. **(Previously Presented)** An isolated human monoclonal antibody which binds to human CD25 and inhibits IL-2 binding to CD25, wherein the antibody comprises a human heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:17, 18 and 19, respectively, and a human light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:20, 21, and 22, respectively.

101. **(Previously Presented)** An isolated human monoclonal antibody which binds to human CD25 and inhibits IL-2 binding to CD25, wherein the antibody comprises a human heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:23, 24, and 25, respectively, and a human light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:26, 27, and 28, respectively.

102. **(Previously Presented)** An isolated human monoclonal antibody which binds to human CD25 and inhibits IL-2 binding to CD25, wherein the antibody comprises a human heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:29, 30, and 31, respectively, and a human light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs:32, 33, and 34, respectively.

103-108. **(Canceled)**